DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Real-time Boerse Frankfurt Warrants 07:20:14 25/06/2024 BST | ||
| 34.73 EUR | +0.03% |
|
| Current month | +3.43% | ||
| 1 month | +3.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 34.73 | +0.03% |
| 24/06/24 | 34.72 | +0.52% |
| 21/06/24 | 34.54 | +1.05% |
| 20/06/24 | 34.18 | +0.41% |
| 19/06/24 | 34.04 | +0.27% |
Real-time Boerse Frankfurt Warrants
Last update June 25, 2024 at 07:20 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC4GWJ |
| ISIN | DE000PC4GWJ2 |
| Date issued | 02/02/2024 |
| Maturity | 20/06/2025 (361 Days) |
| Parity | 1 : 1 |
| Emission price | 35.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 37.61 € |
|---|---|
| Lowest since issue | 33.09 € |
| Spread | 0.2 € |
| Spread % | 0.57% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.23
USD
Average target price
53.19
USD
Spread / Average Target
+25.96%
- Stock Market
- Certificates
- Certificat
